Indeed, almost 60% of cancer-specific A549 enhancers lacked any binding for FOXA1 or NKX2–1 (Fig. 5D), suggesting that the colocalization of FOXA1 and NKX2–1 observed in A549 cells is primarily driven by enhancers preserved in normal tissues. This evidence concerns the gene FOXA1 and cancer.